OUR MISSION:

Nemucore Medical Innovations Inc is dedicated to the improvement of patient care by developing safe, effective precision medicines. By working to know every patient we treat, and engaging patient advocacy groups in constructive ways to enhance patient quality of life, Nemucore is dedicated to forwarding knowledge of precision medicines to become a leader in the development of revolutionary life saving products for improving the care of patients with cancer.

Nemucore Medical Innovations, Inc. is a clinical development company dedicated to the development and commercialization of NMI-900 a life-saving molecularly-targeted therapeutic. NMI-900 is a Best-in-Class Aurora B Kinase inhibitor and this unique mechanism of action could be used to treat newly diagnosed and recurrent cancers.

Nemucore is actively developing NMI-900 and it’s companion diagnostic in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Fighting deadly leukemia by developing a new targeted therapy & diagnostic Chemotherapy, the standard cancer treatment, is largely prescribed by informed guesses. Because this inaccurate method kills both cancerous and healthy cells, patients suffer from nasty side effects and don’t usually get a drug that works for them the first time, if they get one that works at all. We’re developing a targeted therapy for a highly lethal leukemia and a diagnostic to determine which patients will respond well to the drug. We’re about to start Phase 1b/2 of clinical trials.

Chemotherapy, the standard cancer treatment, is largely prescribed by informed guesses. Because this inaccurate method kills both cancerous and healthy cells, patients suffer from nasty side effects and don’t usually get a drug that works for them the first time, if they get one that works at all. We’re developing a targeted therapy for a highly lethal leukemia and a diagnostic to determine which patients will respond well to the drug. We’re about to start Phase 1b/2 of clinical trials.


Timeline: